Effects of oestrogen on phosphatase activity in the ventral prostate of intact, castrated, and androgen-treated castrated, adult rats.

M. Andersson,J. Müntzing
DOI: https://doi.org/10.1111/J.1600-0773.1971.TB00650.X
2009-03-13
Acta Pharmacologica et Toxicologica
Abstract:At the Research Laboratories of AB Leo in Helsingborg Sweden information was sought about the hormonal dependence of phosphatases in the rat ventral prostate. For treatment of rats 4 long-acting estrogens and 2 short-acting estrogens were used. The long-acting estrogens were polyestradiol phosphate (PEP) polydiethylstilbestrol phosphate (PSP) polyestriol phosphate (SEP) and estrodiol-17-undecylate (EU). The short-acting estrogens were honvan and estracyt. In intact rats treated with PEP PSP EU H or E testis weight decreased. Thus these compounds had pronounced antigonadotropic effects. Atrophy of the ventral prostate accompanied the weight decreases this indicating marked reduction in the release of androgen. SEP had only a weak antigonadotropic effect. Alkaline and acid phosphatase activities in the ventral prostate were decreased after castration. Although injection of PEP PSP OR EU into intact rats brought ventral atrophy as great as occurred with castration phosphatase activities remained largely unchanged. Thus estrogens may affect the ventral prostate in ways other than by merely causing a secondary decrease in androgen release. Supporting this hypothesis were the facts that 1) phosphatase activities remained largely unchanged in castrated rats after treatment with PEP PSP EU or E and 2) estrogen increased acid and alkaline phosphatase activities in androgen-treated castrated rats.
What problem does this paper attempt to address?